In primary AML patients, high expression of MDR1 mRNA exhibited moderate correlations with poor therapy response (r = 0.64) and resistance to cytarabine (r = 0.53), and strong correlations with resistance to daunorubicin (r = 0.74) (Figure 3A, Table S9). Here, ABCB1 is linked to acute myeloid leukemia.